Graham Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Graham Capital Management’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.7K	Sell	25,067 -17,674	-41%	-$108K	﹤0.01%	1160
2026 Q1	$328K	Sell	42,741 -5,723	-12%	-$53.1K	0.01%	785
2025 Q4	$548K	Buy	48,464 +17,978	+59%	+$183K	0.01%	597
2025 Q3	$280K	Buy	30,486 +18,434	+153%	+$133K	﹤0.01%	893
2025 Q2	$82.9K	Sell	12,052 -154,191	-93%	-$825K	﹤0.01%	1222
2025 Q1	$479K	Buy	166,243 +21,301	+15%	+$78.2K	0.01%	832
2024 Q4	$681K	Buy	144,942 +53,726	+59%	+$198K	0.01%	620
2024 Q3	$326K	Buy	+91,216	New	+$677K	0.01%	754
2023 Q4	–	Sell	-11,845	Closed	-$52.6K	–	1109
2023 Q3	$52.6K	Sell	11,845 -20,103	-63%	-$87.9K	﹤0.01%	964
2023 Q2	$105K	Sell	31,948 -115,031	-78%	-$338K	﹤0.01%	885
2023 Q1	$419K	Buy	146,979 +125,626	+588%	+$1.13M	0.01%	793
2022 Q4	$155K	Buy	+21,353	New	+$139K	﹤0.01%	983

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Graham Capital Management's FULC Position: Q2 2026 in Review

Graham Capital Management reduced its Fulcrum Therapeutics (FULC) stake by 41% in Q2 2026, selling an estimated $108K and leaving 25,067 shares worth $91.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1160.

Graham Capital Management first reported a position in FULC in Q4 2022 and has held it in 12 quarters since. The position peaked at $681K in Q4 2024. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Graham Capital Management held 25,067 shares of Fulcrum Therapeutics worth $91.7K as of Q2 2026.
Graham Capital Management sold 17,674 Fulcrum Therapeutics shares in Q2 2026, an estimated $108K.
Fulcrum Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1160 holding.
Graham Capital Management first reported a position in Fulcrum Therapeutics in Q4 2022 and has held it in 12 quarters since.
Graham Capital Management's Fulcrum Therapeutics position peaked at $681K in Q4 2024.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.